From:	Trials <trials@uspto.gov></trials@uspto.gov>
Sent:	Wednesday, May 11, 2016 3:06 PM
То:	Frank Calvosa; Trials
Cc:	Nick Cerrito; Eric Stops; Evangeline Shih; Gabriel Brier; Lyndsey Przybylski;
	Joseph.Reisman@knobbe.com; Carol.PitzelCruz@knobbe.com;
	Kerry.Taylor@knobbe.com; BoxRanbaxy332@knobbe.com
Subject:	RE: IPR2016-00024 & IPR2016-00738

Counsel,

The parties are authorized to file a joint motion to terminate the proceedings in each case, along with a copy of the settlement agreement and a separate request that the settlement agreement be treated as business confidential information and be kept separate from the case files under 37 C.F.R. 42.74(c). For guidance on what the joint motion to terminate must include, we direct the parties to case IPR2015-00293, Paper 7 (PTAB Jan. 8, 2015).

The papers shall be filed no later than Monday, May 16.

Thanks, Andrew Kellogg, Supervisory Paralegal Patent Trial and Appeal Board USPTO andrew.kellogg@uspto.gov Direct: 571-272-5366

From: Frank Calvosa [mailto:FrankCalvosa@quinnemanuel.com]
Sent: Wednesday, May 11, 2016 2:32 PM
To: Trials <Trials@USPTO.GOV>
Cc: Nick Cerrito <NickCerrito@quinnemanuel.com>; Eric Stops <EricStops@quinnemanuel.com>; Evangeline Shih
<EvangelineShih@quinnemanuel.com>; Gabriel Brier <GabrielBrier@quinnemanuel.com>; Lyndsey Przybylski
<lyndseyprzybylski@quinnemanuel.com>; Joseph.Reisman@knobbe.com; Carol.PitzelCruz@knobbe.com;
Kerry.Taylor@knobbe.com; BoxRanbaxy332@knobbe.com
Subject: IPR2016-00024 & IPR2016-00738

Dear PTAB,

DOCKE.

We write on behalf of Patent Owner, Jazz Pharmaceuticals, Inc. ("Jazz"), regarding IPR2016-00024 and IPR2016-00738. Specifically, we write to respectfully request authorization to file joint motions to terminate these proceedings. Jazz and Petitioner Ranbaxy Inc. ("Ranbaxy") have entered into a confidential settlement agreement, which resolves the IPRs and the related district court litigations. Ranbaxy joins in Jazz's request.

Jazz and Ranbaxy are available to discuss this issue with the Board tomorrow, if necessary. Counsel for Ranbaxy are copied on this email.

Frank Calvosa Associate Quinn Emanuel Urquhart & Sullivan, LLP

51 Madison Avenue, 22nd Floor New York, NY 10010 212-849-7569 Direct 212-849-7000 Main Office Number 212-849-7100 FAX <u>frankcalvosa@quinnemanuel.com</u> <u>www.quinnemanuel.com</u>

NOTICE: The information contained in this e-mail message is intended only for the personal and confidential use of the recipient(s) named above. This message may be an attorney-client communication and/or work product and as such is privileged and confidential. If the reader of this message is not the intended recipient or agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by e-mail, and delete the original message.